Allergan Aesthetics operates as the medical aesthetics business of AbbVie, following AbbVie's acquisition of Allergan in 2020. The company develops and commercialises products used by healthcare professionals across facial aesthetics, including botulinum toxin treatments, hyaluronic acid dermal fillers and other aesthetic technologies. In the UK, Allergan Aesthetics is an established participant in the professional medical aesthetics market, with products including BOTOX and the Juvéderm range. Its commercial activities encompass healthcare professional education, clinical training, scientific engagement and account support. As part of AbbVie, Allergan Aesthetics combines a global research and development organisation with an established commercial presence in medical aesthetics. The business competes across multiple treatment categories, with its UK portfolio and product indications governed by applicable regulatory approvals.